Pfizer (PFE) EVP McDermott granted 151,576 stock appreciation rights in Form 4

Rhea-AI Filing Summary

Pfizer Inc. Executive Vice President Michael McDermott received a grant of 151,576 Stock Appreciation Rights on March 3, 2026. These rights were acquired at a price of $0.00 per right as a form of equity-based compensation.

According to the disclosure, the stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date. After this grant, McDermott directly holds 151,576 stock appreciation rights.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider McDermott Michael

Role Executive Vice President

Type	Security	Shares	Price	Value
Grant/Award	Stock Appreciation Rights	151,576	$0.00	--

Holdings After Transaction: Stock Appreciation Rights — 151,576 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McDermott Michael

(Last) (First) (Middle)

66 HUDSON BOULEVARD EAST

ATTN: CORPORATE SECRETARY

(Street)

NEW YORK NY 10001-2192

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PFIZER INC [ PFE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Vice President

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Appreciation Rights	$26.58	03/03/2026		A		151,576		03/03/2031(1)	03/03/2031(1)	Common Stock	151,576	$0.0000	151,576	D

Explanation of Responses:

1. The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

	/s/ Shanice A. Reid, by power of atty, for Michael McDermott	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Pfizer (PFE) Executive Vice President Michael McDermott report on this Form 4?

Michael McDermott reported receiving a grant of 151,576 Stock Appreciation Rights from Pfizer. These derivative awards were acquired at $0.00 per right as part of his compensation and increase his directly held stock-based incentive position.

How many Stock Appreciation Rights did Michael McDermott receive from Pfizer (PFE)?

He received 151,576 Stock Appreciation Rights. These rights are a form of derivative equity compensation and, after the reported transaction, McDermott directly holds a total of 151,576 such rights tied to Pfizer common stock.

When will Michael McDermott’s Pfizer (PFE) Stock Appreciation Rights be settled?

The Stock Appreciation Rights will be settled in Pfizer common stock on the fifth anniversary of the grant date. Settlement occurs only after specified vesting requirements are met, according to the reported footnote disclosure.

Are Michael McDermott’s Pfizer (PFE) Stock Appreciation Rights subject to vesting conditions?

Yes, the Stock Appreciation Rights are subject to certain vesting requirements. Only after those vesting conditions are satisfied will the rights be eligible to be settled in shares of Pfizer common stock on the fifth anniversary of the grant date.

Will the Pfizer (PFE) Stock Appreciation Rights be paid in cash or stock?

The Stock Appreciation Rights will be settled in shares of Pfizer common stock. The footnote specifies that, following vesting, settlement occurs in common stock on the fifth anniversary of the grant, rather than as a cash payment.

What ownership type is reported for Michael McDermott’s Pfizer (PFE) Stock Appreciation Rights?

The filing classifies McDermott’s ownership of the Stock Appreciation Rights as direct. The transaction is coded with ownership type and nature indicating he holds these derivative awards personally rather than through an indirect entity.